Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling

Cancer Research

Volumn 64, Issue 20, 2004, Pages 7610-7617

  Ji, Qing ^a   Aoyama, Chisa ^b   Nien, Yih Dar ^a   Liu, Paul I ^b   Chen, Peter K ^b   Chang, Lilly ^a   Stanczyk, Frank Z ^a   Stolz, Andrew ^a,c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^c Hoffman Medical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

20ALPHA HYDROXYSTEROID DEHYDROGENASE; CELL NUCLEUS RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN AKR1C1; PROTEIN AKR1C2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGESTERONE METABOLISM; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; RECEPTOR SENSITIVITY; RECEPTOR UPREGULATION; RNA SYNTHESIS; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

20-HYDROXYSTEROID DEHYDROGENASES; AMINO ACID SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; HUMANS; HYDROXYSTEROID DEHYDROGENASES; IMMUNOHISTOCHEMISTRY; MAMMARY TUMOR VIRUS, MOUSE; MOLECULAR SEQUENCE DATA; PROGESTERONE; PROMOTER REGIONS (GENETICS); RECEPTORS, PROGESTERONE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANSFECTION;

EID: 5644227416     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1608     Document Type: Article

References (52)

1. Ross RK, Paganini-Hill A, Wan PC, et al. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst (Bethesda) 2000;92:328-32.
2. Pike MC, Spicer DV, Dahmoush L, et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17-35.
3. Soyal S, Ismail PM, Li J, et al. Progesterone's role in mammary gland development and tumorigenesis as disclosed by experimental mouse genetics. Breast Cancer Res 2002;4:191-6.
4. Lange CA, Richer JK, Horwitz KB. Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol 1999;13:829-36.
5. Pasqualini JR, Paris J, Sitruk-Ware R, et al. Progestins and breast cancer. J Steroid Biochem Mol Biol 1998;65:225-35.
6. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990;11:266-301.
7. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003;289:3243-53.
8. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288:321-33.
9. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis (Lond) 1998;19:1-27.
10. Harada N. Aromatase and intracrinology of estrogen in hormone-dependent tumors. Oncology (Basel) 1999;57(Suppl 2):7-16.
11. Sasano H, Suzuki T, Harada N. From endocrinology to intracrinology. Endocr Pathol 1998;9:9-20.
12. Chen S, Zhou D, Okubo T, et al. Prevention and treatment of breast cancer by suppressing aromatase activity and expression. Ann N Y Acad Sci 2002;963:229-38.
13. Stocco CO, Zhong L, Sugimoto Y, et al. Prostaglandin F2 alpha-induced expression of 20alpha-hydroxysteroid dehydrogenase involves the transcription factor NUR77. J Biol Chem 2000;275:37202-11.
14. Wiest WG, Kidwell WR, Balogh K. Progesterone catabolism in the rat ovary: a regulatory mechanism for progestational potency during pregnancy. Endocrinology 1968;82:844-59.
15. Milewich L, Gant NF, Schwarz BE, et al. Initiation of human parturition. IX. Progesterone metabolism by placentas of early and late human gestation. Obstet Gynecol 1978;51:278-80.
16. Diaz-Zagoya JC, Wiest WG, Arias F. Metabolism of progesterone by placentas from several mammalian species in vitro. Am J Obstet Gynecol 1979;135:809-13.
17. Penning TM. Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr Rev 1997;18:281-305.
18. Vergnes L, Phan J, Stolz A, et al. A cluster of eight hydroxysteroid dehydrogenase genes belonging to the aldo-keto reductase supergene family on mouse chromosome 13. J Lipid Res 2003;44:503-11.
19. Wilks JW, Spilman CH, Campbell JA. Steroid binding specificity of the hamster uterine progesterone receptor. Steroids 1980;35:697-706.
20. Hara A, Matsuura K, Tamada Y, et al. Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-acid-binding protein and an oxidoreductase of human colon cells. Biochem J 1996;313:373-6.
21. Higaki Y, Usami N, Shintani S, et al. Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chem Biol Interact 2003;143-144:503-13.
22. Zhang Y, Dufort I, Rheault P, et al. Characterization of a human 20alpha-hydroxysteroid dehydrogenase. J Mol Endocrinol 2001;25:221-8.
23. Lou H, Hammond L, Sharma V, et al. Genomic organization and chromosomal localization of a novel human hepatic dihydrodiol dehydrogenase with high affinity bile acid binding. J Biol Chem 1994;269:8416-22.
24. Ji Q, Chang L, VanDenBerg D, et al. Selective reduction of AKR1C2 in prostate cancer and its role in DHT metabolism. Prostate 2003;54:275-89.
25. Pelletier G, Luu-The V, Tetu B, et al. Immunocytochemical localization of type 5 17beta-hydroxysteroid dehydrogenase in human reproductive tissues. J Histochem Cytochem 1999;47:731-8.
26. Han YP, Nien YD, Garner WL. Recombinant human platelet-derived growth factor and transforming growth factor-beta mediated contraction of human dermal fibroblast populated lattices is inhibited by Rho/GTPase inhibitor but does not require phosphatidylinositol-3′ kinase. Wound Repair Regen 2002;10:169-76.
27. Syed V, Ulinski G, Mok SC, et al. M. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001;61:6768-76.
28. Wiebe JP, Muzia D, Hu J, et al. The 4-pregnene and 5alpha-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion. Cancer Res 2000;60:936-43.
29. Anderson E. The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis. Breast Cancer Res 2002;4:197-201.
30. Soule HD, Maloney TM, Wolman SR, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990;50:6075-86.
31. Tomlinson JW, Stewart PM. Cortisol metabolism and the role of 11beta-hydroxysteroid dehydrogenase. Best Pract Res Clin Endocrinol Metab 2001;15:61-78.
32. Bumke-Vogt C, Bahr V, Diederich S, et al. Expression of the progesterone receptor and progesterone-metabolising enzymes in the female and male human kidney. J Endocrinol 2002;175:349-64.
33. Quinkler M, Johanssen S, Bumke-Vogt C, et al. Enzyme-mediated protection of the mineralocorticoid receptor against progesterone in the human kidney. Mol Cell Endocrinol 2001;171:21-4.
34. Johansson ED, Jonasson LE. Progesterone levels in amniotic fluid and plasma from women. I. Levels during normal pregnancy. Acta Obstet Gynecol Scand 1971;50: 339-43.
35. Wiebe JP, Lewis MJ. Activity and expression of progesterone metabolizing 5alpha-reductase, 20alpha-hydroxysteroid oxidoreductase and 3alpha(beta)- hydroxysteroid oxidoreductases in tumorigenic (MCF-7, MDA-MB-231, T-47D) and nontumorigenic (MCF-10A) human breast cancer cells. BMC Cancer 2003;3:9.
36. Burczynski ME, Lin HK, Penning TM. Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res 1999;59:607-14.
37. Perou CM, Jeffrey SS, Van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 1999;96:9212-7.
38. Mori M, Tominaga T, Tamaoki BI. Steroid metabolism in normal mammary gland and in the dimethylbenzanthracene-induced mammary tumor of rats. Endocrinology 1978;102:1387-97.
39. Lewis MJ, Wiebe JP, Heathcote JG. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 2004;4:27.
40. Horwitz KB. The molecular biology of RU486. Is there a role for antiprogestins in the treatment of breast cancer? Endocr Rev 1992;13:146-63.
41. Schoonen WG, Joosten JW, Kloosterboer HJ. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells. II. T47D cell lines. Steroid Biochem Mol Biol 1995;55:439-44.
42. Schoonen WG, Joosten JW, Kloosterboer HJ. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells. I. MCF-7 cell lines. Steroid Biochem Mol Biol 1995;55:423-37.
43. Lin VC, Ng EH, Aw SE, Tan MG, et al. Progestins inhibit the growth of MDA-MB-231 cells transfected with progesterone receptor complementary DNA. Clin Cancer Res 1999;5:395-403.
44. Musgrove EA, Lee CS, Sutherland RL. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 1991;11:5032-43.
45. Hissom JR, Moore MR. Progestin effects on growth in the human breast cancer cell line T-47D: possible therapeutic implications. Biochem Biophys Res Commun 1987; 145:706-11.
46. Eden J. Progestins and breast cancer. Am J Obstet Gynecol 2003;188:1123-31.
47. Longacre TA, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986;10:382-93.
48. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev 1997;18:502-19.
49. Li CI, Malone KE, Porter PL, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 2003;289:3254-63.
50. Conneely OM, Mulac-Jericevic B, DeMayo F, et al. Reproductive functions of progesterone receptors. Recent Prog Horm Res 2002;57:339-55.
51. Richer JK, Jacobsen BM, Manning NG, et al. Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem 2002;277: 5209-18.
52. Weiler PJ, Wiebe JP. Plasma membrane receptors for the cancer-regulating progesterone metabolites, 5alpha-pregnane-3,20-dione and 3alpha-hydroxy-4- pregnen-20-one in MCF- 7 breast cancer cells. Biochem Biophys Res Commun 2000;272:731-7.